| Peer-Reviewed

Efficacy and Safety Outcomes of Monopolar Transurethral Resection of the Prostate in Abuja, Nigeria

Received: 23 June 2022     Accepted: 11 July 2022     Published: 28 July 2022
Views:       Downloads:
Abstract

Introduction: Benign prostatic hyperplasia (BPH) is the most common disease in older men. Its clinical manifestations as lower urinary tract symptoms (LUTS) negatively impact patients’ quality of life. Transurethral resection of prostate (TURP) has held a unique position as the front-line endoscopic treatment of BPH for many decades in developed nations. However, there are few literatures on its use in this environment. Objective: To document the 5-year efficacy and safety outcome of monopolar TURP for the treatment of the LUTS secondary to BPH at Federal Medical Centre (FMC), Abuja. Patients and Methods: A retrospective study of all men who had monopolar TURP with histologic confirmation of BPH between June 2016 and May 2021. The information retrieved includes age, prostate specific antigen (PSA), preoperative and postoperative International Prostate Symptom Score (IPSS), ultrasound prostatic weight, post-void residual (PVR), indications for TURP, operation time, postoperative complications, and histological reports. These data were analyzed using SPSS version 27.0. Results: A total of 142 patients who had M-TURP met the inclusion criteria. The age range was 49-88 years with a mean of 66.04 years. The mean Prostatic weight was 61.27g (range 21-81g) while serum PSA ranged from 1.0 to 10.1ng/ml (mean = 3.73 ng/ml). The average operation time was 59.29 minutes (range= 46-73 minutes). The most common indication for TURP was recurrent acute urinary retention (n=65,45.8%) while bleeding is the leading complication (n=9, 6.3%). There was no TUR syndrome or intraoperative death. However, the transfusion rate was 6.3%. We recorded improvements in IPSS from 21.53 to 3.43. Histological reports revealed BPH only in 82.4% of cases (n= 117) and BPH with prostatitis in 17.6%(n=25). Conclusions: With appropriate patient selection and organized resection technique, monopolar TURP is a feasible, safe and effective surgical option in the management of BPH-related LUTS.

Published in International Journal of Clinical Urology (Volume 6, Issue 2)
DOI 10.11648/j.ijcu.20220602.12
Page(s) 71-75
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

TURP, Prostatic Hyperplasia, Patient Selection

References
[1] Lim, K. B. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017; 4 (3): 148-151. doi: 10.1016/j.ajur.2017.06.004.
[2] Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology. 2002; 59: 245–250. doi: 10.1016/S0090-4295(01)01506-0 [PubMed] [CrossRef] [Google Scholar].
[3] Ketabchi AA, Ketabchi M, Barkam M. The Effect of Modified TURP (M-TURP) in Intra and Postoperative Complications. Nephro-Urol Mon. 2013; 5 (2): 758-61. DOI: 0.5812/numonthly.6607.
[4] Van Venrooij GE, Van Melick HH, Eckhardt MD, Boon TA. Correlations of urodynamic changes with changes in symptoms and well‑being after transurethral resection of the prostate. J Urol 2002; 168: 605‑9.
[5] Madersbacher S, Lackner J, Brössner C, Röhlich M, Stancik I, Willinger M. Prostate Study Group of the Austrian Society of Urology. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation–wide, long–term analysis of 23,123 cases. Eur Urol. 2005; 47: 499–504.
[6] Yucel M, Aras B, Yalcinkaya S, Hatipoglu NK, Aras E. Conventional monopolar transurethral resection of prostate in patients with large prostate (≥80 grams). Cent European J Urol. 2013; 66 (3): 303-8. doi: 10.5173/ceju.2013.03. art13. Epub 2013 Nov 18. PMID: 24707369; PMCID: PMC3974478].
[7] Tubaro A, Carter S, Hind A, Vicentini C, Miano L. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol 2001; 166: 172‑6.
[8] Undie, C. U., Nnana, E. I. & Torporo, K. R. Initial experience with holmium laser enucleation of the prostate in a urology specialist hospital in Nigeria. Afr J Urol 27, 88 (2021). https://doi.org/10.1186/s12301-021-00184-4.
[9] Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU Int. 1999; 83: 227–237. [PubMed] [Google Scholar].
[10] Mayer EK, Kroeze SG, Chopra S et al. Examining the ‘gold standard’: a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU Int 2012; 110: 1,595–1,601.
[11] Lowrance WT, Southwick A, Maschino AC, Sandhu JS. Contemporary Practice Patterns for Endoscopic Surgical Management of Benign Prostatic Hyperplasia (BPH) Among United States Urologists. J Urol. 2013; 189: 1811–1816. [PMC free article] [PubMed] [Google Scholar].
[12] Yu X, Elliott SP, Wilt TJ, McBean AM. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol. 2008; 180: 241–245. [PubMed] [Google Scholar].
[13] Ogbonna BC, Okeahialam BN, Ramyil VM. Alpha–receptor blockade for benign prostatic hyperplasia: uses and problems in a developing country. Br J Urol. 1997; 79: 32–35. [PubMed] [Google Scholar].
[14] Alhasan, S., Aji, S., Mohammed, A. et al. Transurethral resection of the prostate in Northern Nigeria, problems and prospects. BMC Urol 8, 18 (2008). https://doi.org/10.1186/1471-2490-8-18.
[15] Nnabugwu II, Ugwumba FO, Udeh EI, Ozoemena OF. Learning transurethral resection of the prostate: A comparison of the weight of resected specimen to the weight of enucleated specimen in open prostatectomy. Niger J Clin Pract 2017; 20: 1590-5.
[16] Chukwujama N O, Oguike T, Azike J. Transurethral resection of the prostate a 3-year experience. Niger J Surg 2011; 17: 15-8.
[17] Okeke LI. Day case transurethral prostatectomy in Nigeria. West Afr J Med. 2004 Apr-Jun; 23 (2): 128-30. doi: 10.4314/wajm. v23i2.28103. PMID: 15287290.
[18] Akpayak IC, Shuaibu SI, Onowa VE, Nabasu LE, Galam ZZ. Monopolar transurethral resection of the prostate for benign prostatic hyperplasia: What are the outcomes and complications in our patients? Niger JMed2017: 173-177.
[19] Ofoha CG, Raphael JE, Dakum NK, Shu'aibu SI, Akhaine J, Yaki IM. Surgical management of benign prostate hyperplasia in Nigeria: open prostatectomy versus transurethral resection of the prostate. Pan Afr Med J. 2021 Jul 2; 39: 165. doi: 10.11604/pamj.2021.39.165.24767. PMID: 34539961; PMCID: PMC8434791.
[20] Jeje EA, Alabi TO, Ojewola RW, Ogunjimi MA, Tijani KH, Asiyanbi GK. Monopolar transurethral resection of the prostate using water as the irrigation fluid: Our initial experience. Niger Postgrad Med J 2021; 28: 175-80.
[21] Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KA. EUA guidline on assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European Eurology. 2015; 67: 1099–1109.
[22] Moharari RS, Khajavi MR, Khademhosseini P, Hosseini SR, Najafi A. Sterile water as an irrigating fluid for transurethral resection of the prostate: Anesthetical view of the records of 1600 cases. South Med J 2008; 101: 373-5.
[23] Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 50: 969–979; discussion 980. [PubMed] [Google Scholar].
[24] Carlin BI, Bodner DR, Spirnak JP, Resnik MI. Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate 1997; 31: 180-2.
[25] Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo-controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002; 168: 2024-6.
[26] Prescott S, Hadi M, Elton R, Ritchie A, Foubister G, Gould G, et al. (1990) Antibiotic compared with antiseptic prophylaxis for prostatic surgery. British Journal of Urology 66: 509–514. [PubMed] [Google Scholar.
[27] Taylor E, Lindsay G (1988) Antibiotic prophylaxis in transurethral resection of the prostate with reference to the influence of preoperative catheterization. Journal of Hospital Infection 12: 75–83. [PubMed] [Google Scholar].
[28] Ohkawa M, Shimamura M, Tokunaga S, Nakashima T, Orito M. Bacteremia resulting from prostatic surgery in patients with or without preoperative bacteriuria under perioperative antibiotic use. Chemotherapy. 1993 Mar-Apr; 39 (2): 140–6. PMID: 7681366.
[29] R. Donat & B. Mancey-Jones (2002) Incidence of Thromboembolism after Transurethral Resection of the Prostate (TURP) -- A Study on TED Stocking Prophylaxis and Literature Review, Scandinavian Journal of Urology and Nephrology, 36: 2, 119-123, DOI: 10.1080/003655902753679409.
[30] Zheng Zhihuan, Wu Ziqiang, Li Kaixuan, Zhu Quan, Li Haozhen, Liu Xuesong, Wang Guilin, Tang Zhengyan, Wang Zhao (2022) Incidence and Risk Factors of Venous Thromboembolism in Patients After Transurethral Resection of the Prostate (TURP), Journal of Frontiers in Surgery Vol. 8.
[31] Aslam HM, Shahid N, Shaikh NA, Shaikh HA, Saleem S, Mughal A. Spectrum of prostatic lesions. IntArch Med 2013; 6: 36.
[32] Prasopsuk, S., & Tunruttanakul, S. (2021). Safety of a first-day catheter removal after transurethral resection of the prostate (TURP): a propensity score-matched historical control study. Insight Urology, 42 (1), 40–45. https://doi.org/10.52786/isu.a.21.
[33] Chander J, Vanitha V, Lal P, Ramteke VK: Transurethral resection of the prostate as catheter-free day-care surgery. BJU Int 2003; 92: 422–425.
[34] Aslan G, Celebi I, Arslan D, Esen AA: Early catheter removal following transurethral prostatectomy: overnight catheterization. Urol Int 2002; 68: 105–108.
[35] Gordon NSI: Catheter-free same day surgery transurethral resection of the prostate. J Urol 1998; 160: 1709–1712.
Cite This Article
  • APA Style

    Muftau Jimoh Bioku, Ayoleke Ogunrinde, Emmanuel Ugwu, Olatunde Olawoye, Izuchukwu Benerdin Achusi, et al. (2022). Efficacy and Safety Outcomes of Monopolar Transurethral Resection of the Prostate in Abuja, Nigeria. International Journal of Clinical Urology, 6(2), 71-75. https://doi.org/10.11648/j.ijcu.20220602.12

    Copy | Download

    ACS Style

    Muftau Jimoh Bioku; Ayoleke Ogunrinde; Emmanuel Ugwu; Olatunde Olawoye; Izuchukwu Benerdin Achusi, et al. Efficacy and Safety Outcomes of Monopolar Transurethral Resection of the Prostate in Abuja, Nigeria. Int. J. Clin. Urol. 2022, 6(2), 71-75. doi: 10.11648/j.ijcu.20220602.12

    Copy | Download

    AMA Style

    Muftau Jimoh Bioku, Ayoleke Ogunrinde, Emmanuel Ugwu, Olatunde Olawoye, Izuchukwu Benerdin Achusi, et al. Efficacy and Safety Outcomes of Monopolar Transurethral Resection of the Prostate in Abuja, Nigeria. Int J Clin Urol. 2022;6(2):71-75. doi: 10.11648/j.ijcu.20220602.12

    Copy | Download

  • @article{10.11648/j.ijcu.20220602.12,
      author = {Muftau Jimoh Bioku and Ayoleke Ogunrinde and Emmanuel Ugwu and Olatunde Olawoye and Izuchukwu Benerdin Achusi and Quadri Sanni and Ahmed Saad Aliyu},
      title = {Efficacy and Safety Outcomes of Monopolar Transurethral Resection of the Prostate in Abuja, Nigeria},
      journal = {International Journal of Clinical Urology},
      volume = {6},
      number = {2},
      pages = {71-75},
      doi = {10.11648/j.ijcu.20220602.12},
      url = {https://doi.org/10.11648/j.ijcu.20220602.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20220602.12},
      abstract = {Introduction: Benign prostatic hyperplasia (BPH) is the most common disease in older men. Its clinical manifestations as lower urinary tract symptoms (LUTS) negatively impact patients’ quality of life. Transurethral resection of prostate (TURP) has held a unique position as the front-line endoscopic treatment of BPH for many decades in developed nations. However, there are few literatures on its use in this environment. Objective: To document the 5-year efficacy and safety outcome of monopolar TURP for the treatment of the LUTS secondary to BPH at Federal Medical Centre (FMC), Abuja. Patients and Methods: A retrospective study of all men who had monopolar TURP with histologic confirmation of BPH between June 2016 and May 2021. The information retrieved includes age, prostate specific antigen (PSA), preoperative and postoperative International Prostate Symptom Score (IPSS), ultrasound prostatic weight, post-void residual (PVR), indications for TURP, operation time, postoperative complications, and histological reports. These data were analyzed using SPSS version 27.0. Results: A total of 142 patients who had M-TURP met the inclusion criteria. The age range was 49-88 years with a mean of 66.04 years. The mean Prostatic weight was 61.27g (range 21-81g) while serum PSA ranged from 1.0 to 10.1ng/ml (mean = 3.73 ng/ml). The average operation time was 59.29 minutes (range= 46-73 minutes). The most common indication for TURP was recurrent acute urinary retention (n=65,45.8%) while bleeding is the leading complication (n=9, 6.3%). There was no TUR syndrome or intraoperative death. However, the transfusion rate was 6.3%. We recorded improvements in IPSS from 21.53 to 3.43. Histological reports revealed BPH only in 82.4% of cases (n= 117) and BPH with prostatitis in 17.6%(n=25). Conclusions: With appropriate patient selection and organized resection technique, monopolar TURP is a feasible, safe and effective surgical option in the management of BPH-related LUTS.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Efficacy and Safety Outcomes of Monopolar Transurethral Resection of the Prostate in Abuja, Nigeria
    AU  - Muftau Jimoh Bioku
    AU  - Ayoleke Ogunrinde
    AU  - Emmanuel Ugwu
    AU  - Olatunde Olawoye
    AU  - Izuchukwu Benerdin Achusi
    AU  - Quadri Sanni
    AU  - Ahmed Saad Aliyu
    Y1  - 2022/07/28
    PY  - 2022
    N1  - https://doi.org/10.11648/j.ijcu.20220602.12
    DO  - 10.11648/j.ijcu.20220602.12
    T2  - International Journal of Clinical Urology
    JF  - International Journal of Clinical Urology
    JO  - International Journal of Clinical Urology
    SP  - 71
    EP  - 75
    PB  - Science Publishing Group
    SN  - 2640-1355
    UR  - https://doi.org/10.11648/j.ijcu.20220602.12
    AB  - Introduction: Benign prostatic hyperplasia (BPH) is the most common disease in older men. Its clinical manifestations as lower urinary tract symptoms (LUTS) negatively impact patients’ quality of life. Transurethral resection of prostate (TURP) has held a unique position as the front-line endoscopic treatment of BPH for many decades in developed nations. However, there are few literatures on its use in this environment. Objective: To document the 5-year efficacy and safety outcome of monopolar TURP for the treatment of the LUTS secondary to BPH at Federal Medical Centre (FMC), Abuja. Patients and Methods: A retrospective study of all men who had monopolar TURP with histologic confirmation of BPH between June 2016 and May 2021. The information retrieved includes age, prostate specific antigen (PSA), preoperative and postoperative International Prostate Symptom Score (IPSS), ultrasound prostatic weight, post-void residual (PVR), indications for TURP, operation time, postoperative complications, and histological reports. These data were analyzed using SPSS version 27.0. Results: A total of 142 patients who had M-TURP met the inclusion criteria. The age range was 49-88 years with a mean of 66.04 years. The mean Prostatic weight was 61.27g (range 21-81g) while serum PSA ranged from 1.0 to 10.1ng/ml (mean = 3.73 ng/ml). The average operation time was 59.29 minutes (range= 46-73 minutes). The most common indication for TURP was recurrent acute urinary retention (n=65,45.8%) while bleeding is the leading complication (n=9, 6.3%). There was no TUR syndrome or intraoperative death. However, the transfusion rate was 6.3%. We recorded improvements in IPSS from 21.53 to 3.43. Histological reports revealed BPH only in 82.4% of cases (n= 117) and BPH with prostatitis in 17.6%(n=25). Conclusions: With appropriate patient selection and organized resection technique, monopolar TURP is a feasible, safe and effective surgical option in the management of BPH-related LUTS.
    VL  - 6
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Surgery, Federal Medical Centre, Abuja, Nigeria

  • Urology Unit, Department of Surgery, Apirlam Hospital, Abuja, Nigeria

  • Department of Anaesthesia, Federal Medical Centre, Abuja, Nigeria

  • Department of Anaesthesia, Federal Medical Centre, Abuja, Nigeria

  • Department of Anatomic Pathology, Federal Medical Centre, Abuja, Nigeria

  • Department of Surgery, Federal Medical Centre, Abuja, Nigeria

  • Department of Anatomic Pathology, Federal Medical Centre, Abuja, Nigeria

  • Sections